AEterna Zentaris (AEZS) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10, Fidelity Earnings reports. AEterna Zentaris had a return on equity of 20.71% and a net margin of 6.76%. The business had revenue of $0.66 million during the quarter.

AEterna Zentaris stock traded down $0.31 during mid-day trading on Wednesday, hitting $2.06. The company’s stock had a trading volume of 631,507 shares, compared to its average volume of 1,089,230. The company has a market cap of $36.66 million, a P/E ratio of -1.53 and a beta of 0.75. AEterna Zentaris has a 52-week low of $1.12 and a 52-week high of $3.25.

Several equities research analysts have recently commented on the company. Zacks Investment Research raised AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Tuesday, October 9th. ValuEngine downgraded AEterna Zentaris from a “sell” rating to a “strong sell” rating in a report on Monday, September 17th. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $3.25.

TRADEMARK VIOLATION WARNING: “AEterna Zentaris (AEZS) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.wkrb13.com/2018/11/07/aeterna-zentaris-aezs-releases-quarterly-earnings-results-beats-expectations-by-0-10-eps.html.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: How to Track your Portfolio in Google Finance

Earnings History for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply